EU antitrust regulators have asked pharma rivals and customers for feedback in four business areas in light of Novo Holdings' ...

European Union seeks input from rival pharmaceutical firms on Novo Holding $16.5 billion acquisition of Catalent.

EU antitrust regulators have asked pharma rivals and customers for feedback in four business areas in light of Novo Holdings' ...

Catalent is vulnerable to facility closures whether from natural disasters or manufacturing issues, and a warning letter from the FDA or other regulatory agency can result in manufacturing delays or ...

CIBC Asset Management Inc grew its holdings in shares of Catalent, Inc. (NYSE:CTLT – Free Report) by 7.9% in the 3rd quarter, according to the company in its most recent disclosure with the Securities ...

Baird has recently raised Catalent Inc (CTLT) stock to Outperform rating, as announced on November 16, 2023, according to Finviz. Earlier, on September 5, 2023, Argus had raised the stock from a Hold ...

"Given the complexity and scale of our enterprise, we take a team-first mentality and focus," General Counsel Sam Khichi said ...

Halozyme's strategic acquisition of Evotec and innovative ENHANZE technology present growth opportunities. Click here for a ...

OpenText expands its enterprise AI portfolio while demonstrating ROI through real-world implementations and a 30-day proof-of-concept program.

BRUSSELS/LONDON (Reuters) - EU antitrust regulators have asked pharma rivals and customers for feedback in four business areas in light of Novo Holdings' planned $16.5 billion takeover of Catalent ...

Catalent (NYSE:CTLT – Get Free Report) was upgraded by research analysts at StockNews.com from a “sell” rating to a “hold” rating in a report released on Thursday.